Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SAN DIEGO, Oct. 26, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ third quarter 2017 financial results will be released on Thursday, November 2, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, November 2, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 8498419. The live audio webcast can be accessed via the Investor Relations’ section of Apricus’ website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT:
Matthew Beck
[email protected]
The Trout Group
(646) 378-2933
